Zhang Tianbo, Zhang Xialin, Zhang Ningning, Yan Junrong, Wang Lina, Yan Weihong, Yu Zhuanzhuan, Zhang Yonghong, Duan Yanlong, Zhang Ruijuan
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Department of Radiology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Mol Genet Metab Rep. 2024 Mar 26;39:101075. doi: 10.1016/j.ymgmr.2024.101075. eCollection 2024 Jun.
This case report describes a patient initially diagnosed with Gaucher disease (GD) with type I with homozygous mutation c.1448T > C p. (Leu483Pro) at age of 2, presenting with hepatosplenomegaly and cytopenia. Imiglucerase replacement therapy was initiated. At age 17, bilateral hearing loss developed, with subsequent Cranial MRI revealing thalamic damage, leading to a reclassification as type 3 GD. By age of 20, the patient presented with a range of symptoms, including abdominal pain, diarrhea, hypoproteinemia, multiple lymphadenopathy, edema, and Gaucher cell infiltration in the lymph nodes. Comprehensive diagnosis identifies Gaucher tumor and protein-losing enteropathy. Imiglucerase therapy at 90-120 U/kg every 2 weeks significantly improved clinical symptoms, emphasizing the importance of tailored interventions for managing GD manifestations.
本病例报告描述了一名患者,最初在2岁时被诊断为I型戈谢病(GD),存在纯合突变c.1448T>C p.(Leu483Pro),表现为肝脾肿大和血细胞减少。开始使用伊米苷酶替代疗法。17岁时出现双侧听力丧失,随后头颅MRI显示丘脑损伤,导致重新分类为3型GD。到20岁时,患者出现一系列症状,包括腹痛、腹泻、低蛋白血症、多处淋巴结病、水肿以及淋巴结中的戈谢细胞浸润。综合诊断确定为戈谢瘤和蛋白丢失性肠病。每2周以90 - 120 U/kg的剂量进行伊米苷酶治疗显著改善了临床症状,强调了针对GD表现进行个体化干预的重要性。
Mol Genet Metab Rep. 2024-3-26
Children (Basel). 2023-5-12
Turk J Pediatr. 2021
Mol Genet Metab Rep. 2019-7-12
Mol Genet Metab Rep. 2019-5-9
J Pediatr Hematol Oncol. 2017-7
Mol Genet Metab Rep. 2015-12-29
Metabolites. 2025-5-29
Pediatr Hematol Oncol. 2022-5
Turk J Pediatr. 2021
World J Pediatr Congenit Heart Surg. 2020-1
J Inherit Metab Dis. 2020-3
Mol Genet Metab Rep. 2019-5-9
J Pediatr Hematol Oncol. 2017-7
Blood Cells Mol Dis. 2018-2